EMGALITY Reviews (GALCANEZUMAB-GNLM)

Average Rating: 3.3 (3 Ratings)

Filter Results

Compare EMGALITY with similar:
 MIGRAINE HEADACHES

 Type: Biological Drug

  

EMGALITY  (GALCANEZUMAB-GNLM):  Preventive treatment of migraine in adults   (Sources: U.S. Centers for Medicare Services, FDA) FDA Approval Date: 2018-09-27
This drug has a FDA Trial Snapshot showing demographics by sex, age, race, ethnicity for original clinical trial participants.

  

Results are sorted by Date added.

Key to Ratings: 1=LOW (I would not recommend taking this medicine.)
5=HIGH (this medicine cured me or helped me a great deal.)

Page: 1


RATING  REASONSIDE EFFECTS FOR EMGALITYCOMMENTSSEXAGEDURATION/
DOSAGE
DATE ADDED
 
 4  migraine-type headache muscle tightness, achiness, weakness, in particular the lower extremities. It even affected my diaphragm muscle, causing reflux (which i'd never had before) The lower extremity side effect began in the 3rd month of taking Emgality. The reflux began after the 6th month. I also felt fatigue at times, when the muscle symptoms were strongest. It worked great for the headaches- prevented about 85% ! (but i discontinued due to the side effects) M 69 8 months
120 mg 1X M
1/22/2025
Email
 1  Migrane Vertigo Didn't prevent my migrane F 1 months
140 1X M
1/21/2024
Email
 5  Migraine None for certain. This medication has been amazing and I’ve improved in other areas. This has been a life improvement. This helped where other similar medicines did not. There’s a possibility it’s increased Raynauds but even if it has, I consider this medication a necessity. F 48 9 months
One inject
1/4/2021
  

EMGALITY  (GALCANEZUMAB-GNLM):  Preventive treatment of migraine in adults   (Sources: U.S. Centers for Medicare Services, FDA) FDA Approval Date: 2018-09-27
This drug has a FDA Trial Snapshot showing demographics by sex, age, race, ethnicity for original clinical trial participants.

     

BACK TO TOP